Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
641 to 660 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| TMEM41A overexpression correlates with poor prognosis and immune alterations in patients with endometrial carcinoma. | PLoS One | 2023 | 37478120 | PubTator, text mining | PubMed |
| RNautophagic regulation of DNMT3a-dependent DNA methylation by Linc00942 enhances chemoresistance in gastric cancer. | Clin Transl Med | 2023 | 37477089 | PubTator, text mining | PubMed |
| Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer. | BMC Cancer | 2023 | 37474926 | PubTator, text mining | PubMed |
| IGF2BP3-EGFR-AKT axis promotes breast cancer MDA-MB-231 cell growth. | Biochim Biophys Acta Mol Cell Res | 2023 | 37474008 | PubTator, text mining | PubMed |
| Regulatory mechanism of RNA binding motif protein 15-mediated N6 methyladenosine modification in proliferation, invasion, and migration of colorectal cancer cells. | Environ Toxicol | 2023 | 37471637 | PubTator, text mining | PubMed |
| N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment. | Front Endocrinol (Lausanne) | 2023 | 37469973 | PubTator, text mining | PubMed |
| Establishment of a prognostic model based on m6A regulatory factors and stemness of hepatocellular carcinoma using RNA-seq data and scRNA-seq data. | J Cancer Res Clin Oncol | 2023 | 37466793 | PubTator, text mining | PubMed |
| The Difference in Clinical Behavior of Gene Fusions Involving RET/PTC Fusions and THADA/IGF2BP3 Fusions in Thyroid Nodules. | Cancers (Basel) | 2023 | 37444504 | PubTator, text mining | PubMed |
| Integration of Transcriptome and MicroRNA Profile Analysis of iMSCs Defines Their Rejuvenated State and Conveys Them into a Novel Resource for Cell Therapy in Osteoarthritis. | Cells | 2023 | 37443790 | PubTator, text mining | PubMed |
| Role of N6-methyladenosine RNA modification in gastric cancer. | Cell Death Discov | 2023 | 37443100 | PubTator, text mining | PubMed |
| Crosstalk between m6A and coding/non-coding RNA in cancer and detection methods of m6A modification residues. | Aging (Albany NY) | 2023 | 37437245 | PubTator, text mining | PubMed |
| A risk model constructed using 14 N6-methyladenosine-related lncRNAs as a new prognostic marker that correlates with the immunomodulatory effect and drug sensitivity in colorectal cancer. | J Gastrointest Oncol | 2023 | 37435206 | PubTator, text mining | PubMed |
| Functional Role of RBP in Osteosarcoma: Regulatory Mechanism and Clinical Therapy. | Anal Cell Pathol (Amst) | 2023 | 37426488 | PubTator, text mining | PubMed |
| Circular RNA circ-FIRRE interacts with HNRNPC to promote esophageal squamous cell carcinoma progression by stabilizing GLI2 mRNA. | Cancer Sci | 2023 | 37417427 | PubTator, text mining | PubMed |
| CircGNB1 facilitates the malignant phenotype of GSCs by regulating miR-515-5p/miR-582-3p-XPR1 axis. | Cancer Cell Int | 2023 | 37407973 | PubTator, text mining | PubMed |
| Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas. | Biomark Res | 2023 | 37403120 | PubTator, text mining | PubMed |
| Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers. | Front Immunol | 2023 | 37398650 | PubTator, text mining | PubMed |
| Constructing a novel signature and predicting the immune landscape of colon cancer using N6-methylandenosine-related lncRNAs. | Front Genet | 2023 | 37396046 | PubTator, text mining | PubMed |
| Epigenetic modification of m6A regulator proteins in cancer. | Mol Cancer | 2023 | 37391814 | PubTator, text mining | PubMed |
| Necroptosis-Related Prognostic Model for Pancreatic Carcinoma Reveals Its Invasion and Metastasis Potential through Hybrid EMT and Immune Escape. | Biomedicines | 2023 | 37371833 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=33